ClinicalTrials.gg
CompletedNCT01464944Updated Nov 8, 2011

Placebo and Active Controlled Study to Compare the Antipyretic Efficacy of Aspirin® in Patients With Acute Febrile Upper Respiratory Tract Infections Suspected to be of Viral Origin

A Phase 4 interventional study of Acetylsalicylic acid (Aspirin, BAYE4465) and Acetylsalicylic acid (Aspirin, BAYE4465) in Respiratory Tract Infections and Fever, sponsored by Bayer. Completed at 9 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2011-11-08.

Sponsored by Bayer · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
392
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies in Respiratory Tract Infections with a site in Russian Federation — none open to participants now, 1 under way, 1 of them phase 3. Respiratory Tract Infections · Russian Federation.

Started
2003
the only one that year
Phase 4
2 of 10
none open now
Registered
2nd of 10
by date
Lead sponsor
1 of 10
Bayer

Among the 10 studies in Respiratory Tract Infections with a site in Russian Federation, this one is the only one that started in 2003, is one of 2 in phase 4, and was the 2nd registered.

Respiratory Tract Infections

753 studies on the registry are indexed under Respiratory Tract Infections; 114 are open to participants now.

Browse Respiratory Tract Infections studies →

Open to participants now

None of the 10 studies in Respiratory Tract Infections with a site in Russian Federation is open now. The open studies under Respiratory Tract Infections, anywhere →

Who these studies take

Of the 74 Respiratory Tract Infections studies recruiting now, 35 (47%) set no upper age limit and 31 (42%) stop at 75 or younger; 34 take children under 18; 25 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies in Respiratory Tract Infections with a site in Russian Federation as a file.
02

Study summary

This study is addressed to patients suffering from an acute febrile upper respiratory tract infection suspected to be of viral origin. The purpose of this study is to determine the antipyretic efficacy (reduction of fever by lowering the body temperature from a raised state) of Aspirin in doses of 500 and 1000 mg (study medication) compared to the one of Paracetamol in doses of 500 and 1000 mg (comparator medication) as well as the one of Placebo (comparator medication without an active substance). Despite of its common use for fever treatment, the scientific data in adults which support the antipyretic efficacy of Aspirin are sparse. Therefore, the purpose of this study is to collect such data.

03

Conditions studied

  • Respiratory Tract Infections
  • Fever

Keywords

  • Upper Respiratory Tract Infections
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ambulatory male or female patients 18 to 65 years of age
  • Acute uncomplicated febrile URTI suspected to be of viral origin and present not more than 5 days
  • Symptoms of a viral URTI
  • Oral temperature >/= 38.5 °C to \</= 40°C

Exclusion criteria

Exclusion Criteria:

  • Patients with physical findings consistent with the diagnosis of pneumonia, otitis media, bacterial sinusitis or any other bacterial infection of the respiratory tract requiring antibiotics or other therapeutic intervention by a physician
  • Current antibiotic treatment or pre-treatment with antibiotic agents during the last week
  • History or presence of asthma or to ASA, salicylates, paracetamol, or other non-steroidal anti-inflammatory drugs; peptic ulceration or gastric bleeding; hemorrhagic diathesis; hepatic and/or renal dysfunction; Gilbert's disease; Quincke's edema
  • Any other acute or chronic disease which in the opinion f the investigator could interfere with the patient's health and well-being during the conduct of the study or which could interfere with the evaluation of data generated from this subject
  • Any conditions possibly interfering with the gastro-intestinal absorption of the study medication
  • Pregnant or lactating women. All women of childbearing age were to undergo a pregnancy test before start of the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
392 participants (actual)

Study arms

  • Experimental
    Arm 2

    Drug: Acetylsalicylic acid (Aspirin, BAYE4465)

  • Active comparator
    Arm 3

    Drug: Paracetamol

  • Active comparator
    Arm 4

    Drug: Paracetamol

  • Placebo comparator
    Arm 5

    Drug: Placebo

  • Experimental
    Arm 1

    Drug: Acetylsalicylic acid (Aspirin, BAYE4465)

Interventions

  • Acetylsalicylic acid 500 mg orally, single dose, 1 tablet; in addition, 1 Placebo tablet of Acetylsalicylic acid, and 2 Placebo tablets of Paracetamol

  • Acetylsalicylic acid 2 x 500 mg orally, single dose, 2 tablets; in addition, 2 Placebo tablets of Paracetamol

  • Paracetamol 500 mg orally, single dose, 1 tablet; in addition, 1 Placebo tablet of Paracetamol, and 2 Placebo tablets of Acetylsalicylic Acid

  • Paracetamol 2 x 500 mg orally, single dose, 2 tablets; in addition, 2 Placebo tablets of Acetylsalicylic Acid

  • DrugPlacebo

    2 Placebo tablets of Acetylsalicylic Acid, and 2 Placebo tablets of Paracetamol, orally, single dose

06

What researchers measure

Primary outcomes

  1. Area under the curve (AUC) of the orally measured change of body temparature from baseline over a period of 0 - 4 hours post dose.

    Time frame: Up to 4 hours post dose

Secondary outcomes

  1. Maximum temperature difference between baseline and the lowest measured temperature

    Time frame: Up to 4 hours post dose

  2. Time to reach the maximum temperature difference

    Time frame: Up to 4 hours post dose

  3. Intensity of Upper Respiratory Tract Infection symptoms

    Time frame: 0, 2, 4, and 6 hours post dose

  4. Safety - assessment of adverse events

    Time frame: Up to 7 hours post dose

07

Study locations

9 sites
  • Moscow, 105064, Russian Federation
  • Moscow, 107996, Russian Federation
  • Moscow, 109386, Russian Federation
  • Moscow, 125183, Russian Federation
  • Moscow, 127015, Russian Federation
  • Moscow, 127299, Russian Federation
  • Kiev, 02232, Ukraine
  • Kiev, 03049, Ukraine
  • Lugansk, 91011, Ukraine
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2003 and a completion of Apr 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 17, 2011
First posted
Nov 4, 2011
Start
Nov 2003
CompletionActual
Apr 2004
Last update
Nov 8, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 8, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01464944
Lead sponsor
Bayer
First posted
Nov 4, 2011
Start date
Nov 2003
Completion
Apr 2004
Last update
Nov 8, 2011

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aspirin

Start the discussion